GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Posted on by

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial




GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2023:

  • 147,812 shares
  • €530 615.28

During the second half of 2023, total trading was:

  • On the buy side: 1721,869 shares for a total amount of €5,726,529.19
  • On the sell side: 1697,197 shares for a total amount of €5,640,811.12

During this same period, the number of trades were:

  • On the buy side: 2,351
  • On the sell side: 2,016

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

  • 27, 911 shares
  • €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Today, GENFIT has a growing and diversified pipeline with programs at various development stages. The Company’s area of focus is Acute on Chronic Liver Failure (ACLF). Its ACLF franchise consists of five assets in development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE. These are all based on differentiated mechanisms of action leveraging complementary pathways. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA). GENFIT’s track record in bringing early-stage assets with high potential to late development and pre-commercialization stages is highlighted in the successful 52-week Phase 3 ELATIVE® trial evaluating elafibranor in PBC. Beyond therapeutics, GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH) previously known as nonalcoholic steatohepatitis (NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. For more information, visit www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT’s research and development programs. The use of certain words, including “believe”, “potential,” “expect”, “target”, “may” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2022 Universal Registration Document filed with the AMF on April 18, 2023, which is available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2023 or otherwise made public, by the Company. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

GENFIT | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

APPENDIX
H2 2023

 

 

 

 

              
  Buy side Sell side
Date Number of executions Number of shares Traded amounts in EUR Number of executions Number of shares Traded amounts in EUR
TOTAL 2 351 1 721 869 5 726 529,19 2 016 1 697 197 5 640 811,12
03/07/2023 90 119123 417 548,75 64 113328 399 399,60
04/07/2023 61 91000 328 009,50 42 62066 224 907,32
05/07/2023 60 91863 329 731,21 49 93674 338 505,05
06/07/2023 36 56000 203 217,28 16 25999 95 160,50
07/07/2023 10 7501 26 953,64 23 34730 126 346,35
10/07/2023 15 9001 32 973,72 23 17501 64 973,69
11/07/2023 5 4501 16 721,22 17 9191 34 363,59
12/07/2023 15 10361 37 937,01 18 9101 33 486,22
13/07/2023 36 3884 14 279,99 15 6267 23 244,18
14/07/2023 15 7482 27 404,55 7 4722 17 378,47
17/07/2023 8 5304 19 425,26 10 5761 21 225,66
18/07/2023 6 2981 10 939,70 15 4644 17 150,94
19/07/2023 20 4979 18 285,58 7 1516 5 611,70
20/07/2023 10 9181 33 114,49 4 2801 10 153,68
21/07/2023 10 5001 17 866,07 4 5001 18 003,60
24/07/2023 14 11001 39 241,45 15 8001 28 728,63
25/07/2023 18 13311 46 865,10 7 6001 21 198,59
26/07/2023 21 12691 44 345,02 11 8001 28 203,53
27/07/2023 11 10001 34 643,46 13 6001 20 913,42
28/07/2023 20 18001 60 993,51 12 6002 20 416,88
31/07/2023 8 10001 33 533,45 7 2003 6 750,25
01/08/2023 10 5001 16 873,32 16 11001 37 473,26
02/08/2023 21 13605 45 217,71 8 5605 18 714,87
03/08/2023 4 4001 13 193,30 6 6022 20 123,66
04/08/2023 1 1 3,35 16 7980 27 073,03
07/08/2023 1 1 3,41 5 7001 24 263,44
08/08/2023 1 1 3,44 11 7001 24 433,42
09/08/2023 4 1001 3 463,48 3 501 1 738,48
10/08/2023 3 1801 6 135,48 6 4001 13 718,51
11/08/2023 5 4001 14 103,53 25 16901 60 314,09
14/08/2023 3 1001 3 453,46 1 1 3,46
15/08/2023 10 3002 10 212,35 3 360 1 256,40
16/08/2023 8 2300 7 709,51 1 1 3,37
17/08/2023 1 1 3,31 6 2001 6 673,31
18/08/2023 8 5318 17 579,39 6 5361 17 784,10
21/08/2023 11 10184 33 277,24 4 2291 7 422,91
22/08/2023 20 11001 35 043,25 12 9961 33 110,07
23/08/2023 10 7001 22 083,18 19 12001 38 595,70
24/08/2023 19 14001 44 713,17 16 7584 24 628,81
25/08/2023 5 2715 8 592,27 13 8005 25 609,76
28/08/2023 1 1 3,2 16 14414 46 640,97
29/08/2023 4 4501 14 898,31 14 15001 49 996,98
30/08/2023 17 9002 29 639,09 6 1501 5 058,35
31/08/2023 2 1500 4 875,05 7 3001 9 865,79
01/09/2023 4 1501 4 968,33 3 1501 4 998,33
04/09/2023 19 9002 29 616,58 13 4501 14 973,30
05/09/2023 17 5999 19 429,26 7 3000 9 787,47
06/09/2023 21 14287 45 364,08 10 5001 15 953,19
07/09/2023 10 9928 33 675,08 42 41594 142 039,35
08/09/2023 20 17200 61 385,25 12 17201 62 568,64
11/09/2023 15 11350 43 256,10 16 9350 36 214,98
12/09/2023 12 10467 38 788,82 5 2028 7 606,89
13/09/2023 16 8001 29 173,65 14 10001 36 948,69
14/09/2023 15 9001 33 113,78 12 7001 25 833,76
15/09/2023 16 7001 25 493,65 3 2001 7 343,67
18/09/2023 20 9501 33 486,65 1 1 3,63
19/09/2023 8 11557 39 525,06 1 1 3,49
20/09/2023 5 904 3 118,79 9 10001 34 765,98
21/09/2023 14 19842 67 125,09 5 1960 6 869,78
22/09/2023 28 17117 54 700,97 6 29958 95 766,14
25/09/2023 10 14001 43 463,30 2 358 1 159,92
26/09/2023 19 20001 59 993,00 51 68644 218 896,11
27/09/2023 25 15001 46 715,36 1 1 3,21
28/09/2023 16 16846 51 983,05 31 31848 98 878,80
29/09/2023 17 8617 26 973,54 19 11999 37 631,74
02/10/2023 37 19880 61 440,33 18 6496 20 281,23
03/10/2023 9 8001 23 882,99 7 2721 8 297,47
04/10/2023 1 1 2,93 1 1 2,93
05/10/2023 23 18720 55 269,68 21 20001 59 297,96
06/10/2023 20 10001 29 502,95 36 24001 71 203,05
09/10/2023 19 14001 42 443,05 34 15044 45 998,38
10/10/2023 42 22101 66 413,95 47 26002 78 445,95
11/10/2023 20 8547 27 024,76 28 17252 53 928,89
12/10/2023 11 10211 31 938,37 7 5001 15 683,14
13/10/2023 41 16441 50 597,67 9 6035 18 583,39
16/10/2023 8 6001 18 183,03 14 7967 24 289,47
17/10/2023 26 14246 43 329,07 28 14034 42 858,85
18/10/2023 32 13293 40 352,90 8 7878 24 076,59
19/10/2023 43 27901 81 730,12 20 10247 30 137,55
20/10/2023 7 5396 15 484,31 15 10292 29 964,54
23/10/2023 7 2202 6 419,84 7 2202 6 466,68
24/10/2023 30 14530 44 109,16 23 19612 59 457,90
25/10/2023 34 19473 57 263,67 11 7184 21 076,56
26/10/2023 13 10000 29 040,00 14 14818 43 434,37
27/10/2023 43 12561 37 911,23 21 13413 40 738,37
30/10/2023 15 17065 51 278,11 11 8001 24 133,02
31/10/2023 8 4002 12 165,96 9 8001 24 352,96
01/11/2023 22 17776 53 512,69 18 8847 26 791,72
02/11/2023 26 25501 78 420,42 38 40987 126 130,11
03/11/2023 21 11794 36 925,24 27 27380 86 190,87
06/11/2023 26 17273 53 180,63 7 4080 12 537,47
07/11/2023 8 4817 14 813,33 15 18010 56 002,28
08/11/2023 4 2157 6 772,98 3 2845 8 990,17
09/11/2023 15 7512 23 658,44 44 32668 104 008,05
10/11/2023 41 29520 90 918,06 11 10876 33 474,48
13/11/2023 1 1 3,08 18 15313 48 576,66
14/11/2023 59 41127 132 912,59 71 26459 86 146,54
15/11/2023 49 27766 86 897,86 14 12766 40 228,35
16/11/2023 22 8263 25 391,21 11 6183 19 158,83
17/11/2023 27 14427 44 149,51 16 11342 34 912,72
20/11/2023 3 1624 5 088,56 14 14812 46 415,33
21/11/2023 27 14385 44 637,52 3 1362 4 208,63
22/11/2023 7 2022 6 206,04 6 668 2 062,61
23/11/2023 20 9134 27 505,85 2 190 575,68
24/11/2023 33 19664 59 441,72 11 18962 57 887,76
27/11/2023 17 6269 18 744,18 8 2305 6 932,26
28/11/2023 13 8884 26 497,60 12 8832 26 533,98
29/11/2023 17 9905 29 557,31 10 4921 14 809,36
30/11/2023 9 9899 29 623,95 69 29899 90 496,80
01/12/2023 13 9744 29 170,13 7 6708 20 159,69
04/12/2023 22 9332 27 988,07 26 19224 58 211,62
05/12/2023 14 6439 19 131,30 10 5332 15 972,17
06/12/2023 13 8242 24 183,76 15 13993 41 480,57
07/12/2023 7 6855 20 627,17 25 35355 109 064,16
08/12/2023 36 18001 57 693,02 31 33001 105 578,78
11/12/2023 10 8501 27 695,75 15 13631 44 908,69
12/12/2023 33 15520 53 221,96 21 18663 63 337,74
13/12/2023 22 8274 28 875,68 25 11501 40 148,15
14/12/2023 21 10001 36 406,04 17 6001 21 868,54
15/12/2023 12 6001 21 778,59 9 3787 13 772,49
18/12/2023 22 12501 46 991,13 15 8715 32 859,38
19/12/2023 34 31865 115 748,98 17 19190 70 395,44
20/12/2023 15 18606 66 111,40 6 10160 36 298,02
21/12/2023 43 42128 144 507,04 15 19558 67 147,31
22/12/2023 25 14931 50 798,40 20 19222 66 259,39
27/12/2023 27 31000 109 565,47 33 40468 143 914,73
28/12/2023 12 12401 44 612,10 12 12037 43 542,28
29/12/2023 29 46000 164 321,20 18 16984 61 240,40

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com

Attachment